Publication:
Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins.

dc.contributor.authorFernández-Pisonero, Isabel
dc.contributor.authorLorenzo-Martín, L Francisco
dc.contributor.authorDrosten, Mattias
dc.contributor.authorSantos, Eugenio
dc.contributor.authorBarbacid, Mariano
dc.contributor.authorAlarcón, Balbino
dc.contributor.authorBustelo, Xosé R
dc.contributor.funderLa Caixa
dc.contributor.funderAsociaciacion Española Contra el Cancer
dc.contributor.funderMCIN/AEI
dc.date.accessioned2025-06-18T08:46:08Z
dc.date.available2025-06-18T08:46:08Z
dc.date.issued2025-07
dc.description.abstractR-RAS2/TC21, a member of the R-RAS subfamily of GTP-binding proteins, shares structural and signaling properties with the RAS subfamily proteins H-, K-, and N-RAS. However, little information is available regarding its role in normal cells and the level of functional redundancy with R-RAS and classical RAS proteins. In this work, we used loss and gain-of-function approaches to assess these issues in mouse embryonic fibroblasts (MEFs). Using primary MEFs from Rras2, Rras or Rras; Rras2 embryos, we show here that endogenous R-RAS2/TC21 is required for activation of the phosphatidylinositol 3 kinase (PI3K)-AKT axis, the proliferation, and the adhesion properties of these cells. Endogenous R-RAS does not influence any of these cell parameters. We also show that the depletion of R-RAS2/TC21 worsens the proliferative and morphological defects elicited by the combined loss of H-, K- and N-RAS proteins in MEFs. Conversely, the ectopic expression of an active version of R-RAS2/TC21, but not of R-RAS, overcomes such defects. This rescue activity involves the inhibition of the tumor suppressor TP53 and is PI3K-, mTORC-, and MEK/ERK-dependent. These results indicate that R-RAS2/TC21, R-RAS, and RAS subfamily GTPases play different roles in MEFs. They also show that R-RAS2 provides subsidiary signals that are essential for the short-term proliferation and long-term viability of MEFs lacking RAS signaling.
dc.description.peerreviewed
dc.description.tableofcontentsThe XRB's project leading to these results has received funding from the Spanish Association against Cancer (GC16173472GARC), the Castilla-Leon government (CSI018P23), grants funded by MCIN/AEI/10.13039/501100011033/ plus the European Research Development Fund << A way of making Europe >> of the European Union (PID2021-122666OB-I00, PDC2022-133027-I00, PLEC2022-009217), << la Caixa >> Banking Foundation (HR20-00164), the << Programa Excelencia >> of the Fundacion Cientifica AECC 2022 (EPAEC222641CICS), and the << Escalera de Excelencia >> of the Education Ministry of the Castilla y Leon autonomous government plus the European Research Development Fund (CLU-2023-2-01).
dc.format.number24
dc.format.page1905-1921
dc.format.volume44
dc.identifier.citationOncogene . 2025 Jul;44(24):1905-1921.
dc.identifier.journalOncogene
dc.identifier.pubmedID40164870
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26763
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-122666OB-I00/ES/DISECCION DEL PAPEL PATOBIOLOGICO Y TERAPEUTICO DE UN NUEVO DRIVER ONCOGENICO EN LINFOMAS DE CELULAS T/
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PDC2022-133027-I00/ES/OPTIMIZACION ORIENTADA AL MERCADO THE INHIBIDORES DE LA ACTIVIDAD CATALITICA DE LA ONCOPROTEINA VAV1/
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PLEC2022-009217/ES/ENCAPSULACIÓN DE CÉLULAS CART EN SISTEMAS POROSOS NANOESTRUCTURADOS BIOACTIVOS PARA SU LIBERACIÓN DIRIGIDA EN TUMORES SOLIDOS/
dc.relation.projectIDE
dc.relation.publisherversionhttp://doi: 10.1038/s41388-025-03367-3.
dc.repisalud.institucionCNIO
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Oncología Experimental
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHUMAN R-RAS
dc.subjectTC21
dc.subjectACTIVATION
dc.subjectTRANSFORMATION
dc.subjectMIGRATION
dc.subjectPROLIFERATION
dc.subjectTC21/R-RAS2
dc.subjectEXPRESSION
dc.subjectKINASE
dc.titleActive R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication728b1f96-276b-4ab5-8640-8964fb72939f
relation.isAuthorOfPublication.latestForDiscovery728b1f96-276b-4ab5-8640-8964fb72939f

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ActiveRRAS2TC21prevents_2025.pdf
Size:
12.74 MB
Format:
Adobe Portable Document Format